Apex Trader Funding - News
Calliditas Interim Report January to June 2024
STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (STO: CALTX) :
April to June 2024 (compared to April to June 2023)
Net sales amounted to SEK 559.8 million, of which TARPEYO® net sales amounted to SEK 493.4 million, for the three months ended June 30, 2024. For the three months ended June 30, 2023, net sales amounted to SEK 269.4 million, of which TARPEYO net sales amounted to SEK 259.2 million.
Operating loss amounted to SEK 31.5 million and SEK 75.2 million for the three months ended June 30, 2024, and 2023, respectively. However, expenses related to the Asahi Kasei offer and expenses related to provisions for social security contribution for incentive programs were included in the second quarter, totaling SEK 101.7 million. Excluding these expenses, the adjusted operating profit1 amounted to SEK 70.2 million for the three months ended June 30, 2024.
Loss per share before and after dilution amounted to SEK 0.88 and SEK 1.71 for the three months ended June 30, 2024, and 2023, respectively.
Cash amounted to SEK 797.3 million and SEK 866.2 million as of June 30, 2024, and 2023, respectively.
January to June 2024 (compared to January to June 2023)
Net sales amounted to SEK 855.3 million, of which TARPEYO® net sales amounted to SEK 771.6 million, for the six months ended June 30, 2024. For the six months ended June 30, 2023, net sales amounted to SEK 460.7 million, of which TARPEYO net sales amounted to SEK 444.9 million.
Operating loss amounted to SEK 235.3 million and SEK 255.2 million for the six months ended June 30, 2024, and 2023, respectively. However, expenses related to the Asahi Kasei offer and expenses related to provisions for social security contribution for incentive programs were included in the second quarter, totaling SEK 101.7 million. Excluding these expenses the adjusted operating loss1 amounted to SEK 133.6 million for the six months ended June 30, 2024.
Loss per share before and after dilution amounted to SEK 5.47 and SEK 5.21 for the six months ended June 30, 2024, and 2023, respectively.